We Offer Worldwide Shipping
Login Wishlist

Empagliflozin

$192

  • Brand : BIOFRON

  • Catalogue Number : BN-O1227

  • Specification : 95%(HPLC)

  • CAS number : 864070-44-0

  • Formula : C23H27ClO7

  • Molecular Weight : 450.91

  • PUBCHEM ID : 11949646

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1227

Analysis Method

Specification

95%(HPLC)

Storage

-20℃

Molecular Weight

450.91

Appearance

Powder

Botanical Source

Structure Type

Category

SMILES

C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl

Synonyms

X5927/Empagliflozin/(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol/D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S)-/Jardiance/CS-0940/BI10773/(1S)-1,5-Anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydro-3-furanyloxy]benzyl}phenyl)-D-glucitol

IUPAC Name

Density

1.4±0.1 g/cm3

Solubility

Flash Point

355.7±31.5 °C

Boiling Point

664.5±55.0 °C at 760 mmHg

Melting Point

InChl

InChl Key

OBWASQILIWPZMG-QZMOQZSNSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:864070-44-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

30008607

Abstract

Objectives: In Japan, sodium-glucose co-transporter type 2 (SGLT2) inhibitors have been reported to be associated with serious skin and subcutaneous tissue disorders. A post-marketing surveillance (PMS) study suggested that the association was specific for ipragliflozin and, to a lesser extent for dapagliflozin. These studies were performed to confirm the association of 6 SGLT2 inhibitors with serious skin disorders in a clinical setting, to elucidate the role of melanin in serious skin disorders and to understand the underlying mechanisms.

Methods: The latest PMS records were retrieved from the Japanese Adverse Drug Event Report (JADER) database, and the associations were analyzed by data mining techniques. In silico 3-D docking simulation of SGLT2 inhibitors with melanin was performed using the MOE software. The skin tissue distribution of SGLT2 inhibitors was evaluated using albino rats after oral administration at clinical doses.

Results: The adjusted reporting odds ratio (95% confidential limit) was 1.667 (1.415, 1.963) for ipragliflozin, 0.514 (0.317, 0.835) for dapagliflozin, 0.149 (0.048, 0.465) for tofogliflozin, 0.624 (0.331, 1.177) for luseogliflozin, 0.590 (0.277, 1.257) for canagliflozin and 0.293 (0.073, 1.187) for empagliflozin, when drugs other than the SGLT2 inhibitors were referred, and the association was detected only for ipragliflozin in clinical use. In silico 3-D docking simulation suggested the influence of melanin in ipragliflozin-specific serious skin disorders. The skin tissue-to-plasma concentration ratio of ipragliflozin was 0.45 ± 0.20 (±SD) at 1 hr after administration and increased in a time-dependent manner to 5.82 ± 3.66 at 24 hr (p<0.05), but not in case of other SGLT2 inhibitors. Conclusions: Serious skin disorders were suggested to be specific for ipragliflozin. Interaction with melanin might be implicated in ipragliflozin-specific serious skin disorders. Ipragliflozin was retained in the skin tissue, which suggested its interaction with the skin tissue in serious skin disorders.

KEYWORDS

Sodium-glucose co-transporter type 2 (SGLT2), skin and subcutaneous tissue disorders, ipragliflozin, dapagliflozin

Title

Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors

Author

Toshiyuki Sakaeda,1,✉ Shinji Kobuchi,1 Ryosuke Yoshioka,1 Mariko Haruna,1 Noriko Takahata,1 Yukako Ito,1 Aki Sugano,2 Kazuki Fukuzawa,3 Toshiki Hayase,3 Taro Hayakawa,4 Hideo Nakayama,4 Yutaka Takaoka,2 and Masahiro Tohkin3

Publish date

2018;


Description :

Empty ...